Moatazedi, who held multiple leadership positions in the medical aesthetics space, noted the rise and transformation of medical aesthetics — particularly neurotoxins — in the last two decades. or younger views it very differently than their parents,” Moatazedi said. “The older generation was introduced to medical aesthetics through a traditional medical doctor route.”, dermatology skin care centers and plastic surgery.
Moatazedi noted that Evolus is very different from its competitors. “When investors invest in us, generally they’re investing in biotech companies — they don’t really understand the world of medical aesthetics. On the consumer side, they look at us as a beauty brand. We’re bridging a new language that will change over time.”
The performance side of the company is no different than pharmaceutical companies when it comes to being FDA-approved and having lengthy development cycles. Evolus’ hallmark product Jeuveau is the fastest-growing aesthetic toxin with 12 percent of the market and was in development for six years and celebrated its fifth anniversary at the Beauty CEO Summit.